If you or a loved one is taking Tysabri for multiple sclerosis or Crohn's disease, the possibility of progressive multifocal leukoencephalopathy (PML) can be deeply concerning. The FDA warning highlights a clear link, yet the evidence has boundaries that affect how we interpret risk. Building on decades of pharmacovigilance research, this page examines what the scientific record actually shows—and what questions remain unanswered.
While the FDA warning primarily addresses patient risk, the same pharmacological properties that increase PML risk in patients also pose potential hazards to healthcare workers who handle Tysabri. The drug's mechanism—inhibiting lymphocyte migration into the central nervous system—could theoretically affect anyone with systemic exposure. Although occupational exposure is typically lower than therapeutic doses, accidental needle sticks, spills, or inhalation of aerosolized particles during preparation may lead to absorption. Therefore, understanding the patient risk profile is essential for evaluating occupational safety. This section bridges the established patient-centered evidence with the emerging concern for healthcare professionals, emphasizing that the same risk factors (e.g., JC virus serostatus, duration of exposure) may apply in occupational settings, albeit with different exposure levels.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These clinical trial data demonstrate that PML can occur within the first year of treatment, as seen in the Crohn's disease patient, and also after longer exposure, as seen in the multiple sclerosis patients.
The mechanistic pathway linking Tysabri to PML involves the drug's action on the immune system. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the central nervous system. This immunosuppressive effect can allow reactivation of latent JC virus, which then infects oligodendrocytes in the brain, leading to demyelination and the clinical syndrome of PML. The boxed warning notes that PML is an opportunistic viral infection that typically only occurs in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is addressed by the boxed warning and the TOUCH Prescribing Program. The boxed warning clearly states that Tysabri increases the risk of PML and lists the known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning instructs healthcare professionals to monitor patients and withhold Tysabri at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The restricted distribution program is designed to ensure that only patients who understand the risks and are monitored appropriately receive the drug. For affected patients, causation-related considerations include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between exposure and documented harm varies. In clinical trials, PML occurred after eight doses (approximately 8 weeks) in one patient and after a median of 120 weeks in two patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that PML can develop both early and late during treatment. FDA adverse-event reports from the FAERS database list fatigue, multiple sclerosis relapse, headache, gait disturbance, and fall among the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most frequently reported events in this database, its occurrence is specifically highlighted in the boxed warning and clinical trial data.
In summary, Tysabri carries a well-documented risk of PML, with known risk factors including anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. The boxed warning and restricted distribution program aim to mitigate this risk through monitoring and early intervention. The timeline for PML development can range from weeks to years of treatment, and affected patients should be evaluated for the presence of risk factors and the timing of exposure. For healthcare workers with occupational exposure, similar risk factors may apply, though data are limited. Ongoing surveillance and adherence to safety protocols are essential to minimize risk. References: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI)
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The FDA has issued a boxed warning for Tysabri (natalizumab) stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The warning instructs healthcare professionals to monitor patients for signs of PML and to withhold Tysabri immediately if symptoms appear. Tysabri is only available through a restricted distribution program called TOUCH (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three main risk factors increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML can develop both early and late during Tysabri treatment. In clinical trials, one patient developed PML after eight doses (approximately 8 weeks), while two patients developed PML after a median of 120 weeks of treatment. This indicates that the timeline can range from weeks to years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.